DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Krentz, 2008, New drugs for type 2 diabetes mellitus: what is their place in therapy?, Drugs, 68, 2131, 10.2165/00003495-200868150-00005
Monami, 2011, Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials, Diabetes Metab Res Rev, 27, 362, 10.1002/dmrr.1184
Phung, 2010, Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes, JAMA, 303, 1410, 10.1001/jama.2010.405
Bennett, 2011, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations, Ann Intern Med, 154, 602, 10.7326/0003-4819-154-9-201105030-00336
Scheen, 2012, A review of gliptins in 2011, Exp Opin Pharmacother, 13, 81, 10.1517/14656566.2012.642866
Neumiller, 2010, Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus, Pharmacotherapy, 30, 463, 10.1592/phco.30.5.463
Scheen, 2010, Addition of incretin therapy to metformin in type 2 diabetes, Lancet, 375, 1410, 10.1016/S0140-6736(10)60399-6
Fakhoury, 2010, A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes, Pharmacology, 86, 44, 10.1159/000314690
Gautier, 2011, Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes, Ann Endocrinol (Paris), 72, 287, 10.1016/j.ando.2011.05.005
Nathan, 2009, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia, 52, 17, 10.1007/s00125-008-1157-y
Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540
Schweizer, 2007, Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes, Diabet Med, 24, 955, 10.1111/j.1464-5491.2007.02191.x
Goldstein, 2007, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes, Diabetes Care, 30, 1979, 10.2337/dc07-0627
Williams-Herman, 2009, Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study, Curr Med Res Opin, 25, 569, 10.1185/03007990802705679
Williams-Herman, 2010, Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes, Diabetes Obes Metab, 12, 442, 10.1111/j.1463-1326.2010.01204.x
Aschner, 2010, Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes, Diabetes Obes Metab, 12, 252, 10.1111/j.1463-1326.2009.01187.x
Goke, 2008, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin, Horm Metab Res, 40, 892, 10.1055/s-0028-1082334
Schweizer, 2009, Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial, Diabetes Obes Metab, 11, 804, 10.1111/j.1463-1326.2009.01051.x
Bosi, 2009, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus, Diabetes Obes Metab, 11, 506, 10.1111/j.1463-1326.2009.01040.x
Jadzinsky, 2009, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial, Diabetes Obes Metab, 11, 611, 10.1111/j.1463-1326.2009.01056.x
Pfutzner, 2011, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks, Diabetes Obes Metab, 13, 567, 10.1111/j.1463-1326.2011.01385.x
Rosenstock, 2007, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes, Diabetes Obes Metab, 9, 175, 10.1111/j.1463-1326.2006.00698.x
Rosenstock, 2010, Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes, Diabetes Care, 33, 2406, 10.2337/dc10-0159
Rosenstock, 2007, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial, Diabetes Care, 30, 217, 10.2337/dc06-1815
Pan, 2008, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial, Diabet Med, 25, 435, 10.1111/j.1464-5491.2008.02391.x
Kawamori, 2010, Linagliptin provides superior glycemic control compared to voglibose as monotherapy in Japanese patients with type 2 diabetes, Diabetes, 59, A172
Nauck, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 9, 194, 10.1111/j.1463-1326.2006.00704.x
Seck, 2010, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, Int J Clin Pract, 64, 562, 10.1111/j.1742-1241.2010.02353.x
Arechavaleta, 2011, Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 13, 160, 10.1111/j.1463-1326.2010.01334.x
Ferrannini, 2009, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes Obes Metab, 11, 157, 10.1111/j.1463-1326.2008.00994.x
Matthews, 2010, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study, Diabetes Obes Metab, 12, 780, 10.1111/j.1463-1326.2010.01233.x
Filozof, 2010, A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study, Diabet Med, 27, 318, 10.1111/j.1464-5491.2010.02938.x
Goke, 2010, Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial, Int J Clin Pract, 64, 1619, 10.1111/j.1742-1241.2010.02510.x
Forst, 2010, Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes, Diabet Med, 27, 1409, 10.1111/j.1464-5491.2010.03131.x
Scott, 2008, Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 10, 959, 10.1111/j.1463-1326.2007.00839.x
Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9
Bolli, 2008, Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study, Diabetes Obes Metab, 10, 82, 10.1111/j.1463-1326.2007.00820.x
Bolli, 2009, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin, Diabetes Obes Metab, 11, 589, 10.1111/j.1463-1326.2008.01023.x
Blonde, 2009, Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study, Diabetes Obes Metab, 11, 978, 10.1111/j.1463-1326.2009.01080.x
Pratley, 2010, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, Lancet, 375, 1447, 10.1016/S0140-6736(10)60307-8
Pratley, 2011, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int J Clin Pract, 65, 397, 10.1111/j.1742-1241.2011.02656.x
Scheen, 2010, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes Metab Res Rev, 26, 540, 10.1002/dmrr.1114
Chapell, 2009, Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone, Diabetes Obes Metab, 11, 1009, 10.1111/j.1463-1326.2009.01084.x
DeFronzo, 2010, Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials, Diabet Med, 27, 309, 10.1111/j.1464-5491.2010.02941.x
Hermansen, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, Diabetes Obes Metab, 9, 733, 10.1111/j.1463-1326.2007.00744.x
Garber, 2008, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea, Diabetes Obes Metab, 10, 1047, 10.1111/j.1463-1326.2008.00859.x
Pratley, 2009, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy, Diabetes Obes Metab, 11, 167, 10.1111/j.1463-1326.2008.01016.x
Lewin, 2010, Woerle H-J. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes, Diabetologia, 53
Chacra, 2009, Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, Int J Clin Pract, 63, 1395, 10.1111/j.1742-1241.2009.02143.x
Chacra, 2011, Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks, Diabetes Vasc Dis Res, 8, 150, 10.1177/1479164111404574
De Fronzo, 2009, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028
Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007
Garber, 2007, Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study, Diabetes Obes Metab, 9, 166, 10.1111/j.1463-1326.2006.00684.x
Hollander, 2009, Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone, J Clin Endocrinol Metab, 94, 4810, 10.1210/jc.2009-0550
Pratley, 2009, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Curr Med Res Opin, 25, 2361, 10.1185/03007990903156111
Kaku, 2011, Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study, Diabetes Obes Metab, 13, 1028, 10.1111/j.1463-1326.2011.01460.x
Hollander, 2011, Safety and efficacy of saxagliptin added to thiazolidinedione over 76weeks in patients with type 2 diabetes mellitus, Diabetes Vasc Dis Res, 8, 125, 10.1177/1479164111404575
Gomis, 2011, Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 13, 653, 10.1111/j.1463-1326.2011.01391.x
Derosa, 2010, Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients, Metabolism, 59, 887, 10.1016/j.metabol.2009.10.007
Derosa, 2010, Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients, Horm Metab Res, 42, 663, 10.1055/s-0030-1255036
Mikhail, 2008, Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential, Vasc Health Risk Manag, 4, 1221, 10.2147/VHRM.S3374
Scheen, 2009, Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17), Diabet Med, 26, 1033, 10.1111/j.1464-5491.2009.02816.x
Hsia, 2011, Sitagliptin compared to thiazolidinediones as a third-line oral anti- hyperglycemic agent in type 2 diabetes mellitus, Endocr Pract, 17, 691, 10.4158/EP10405.OR
Owens, 2011, Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study, Diabet Med, 28, 1352, 10.1111/j.1464-5491.2011.03387.x
Bosi, 2011, Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study, Diabetes Obes Metab, 13, 1088, 10.1111/j.1463-1326.2011.01463.x
Fonseca, 2007, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabetologia, 50, 1148, 10.1007/s00125-007-0633-0
Vilsboll, 2010, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 12, 167, 10.1111/j.1463-1326.2009.01173.x
Rosenstock, 2009, Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia, Diabetes Obes Metab, 11, 1145, 10.1111/j.1463-1326.2009.01124.x
Barnett, 2011, Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy, Diabetologia, 54, S108
Hollander, 2011, Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial, Diabetes Obes Metab, 13, 268, 10.1111/j.1463-1326.2010.01351.x
Reasner, 2011, The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 13, 644, 10.1111/j.1463-1326.2011.01390.x
Yoon, 2011, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes, Int J Clin Pract, 65, 154, 10.1111/j.1742-1241.2010.02589.x
Ahren, 2008, Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin, Vasc Health Risk Manag, 4, 383, 10.2147/VHRM.S1944
Neumiller, 2009, Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors, J Am Pharm Assoc (2003), 49, S16, 10.1331/JAPhA.2009.09078
Gallwitz, 2011, GLP-1 agonists and dipeptidyl-peptidase IV inhibitors, Handb Exp Pharmacol, 203, 53, 10.1007/978-3-642-17214-4_3
DeFronzo, 2008, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study, Curr Med Res Opin, 24, 2943, 10.1185/03007990802418851
Wysham, 2011, DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide, Diabet Med, 28, 705, 10.1111/j.1464-5491.2011.03301.x
Baetta, 2011, Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences, Drugs, 71, 1441, 10.2165/11591400-000000000-00000
Scheen, 2011, Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation), Exp Opin Drug Metab Toxicol, 7, 1561, 10.1517/17425255.2011.628986
Signorovitch, 2011, Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials, Clin Drug Invest, 31, 665, 10.2165/11592490-000000000-00000
Abe, 2011, Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice, Curr Drug Metab, 12, 57, 10.2174/138920011794520053
Scheen, 2010, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors, Diabetes Obes Metab, 12, 648, 10.1111/j.1463-1326.2010.01212.x
Chan, 2008, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes Obes Metab, 10, 545, 10.1111/j.1463-1326.2008.00914.x
Meyers, 2011, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment, Postgrad Med, 123, 133, 10.3810/pgm.2011.05.2291
Nowicki, 2011, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment, Diabetes Obes Metab, 13, 523, 10.1111/j.1463-1326.2011.01382.x
Nowicki, 2011, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study, Int J Clin Pract, 65, 1230, 10.1111/j.1742-1241.2011.02812.x
Banerji, 2010, Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study, Diabetes Res Clin Pract, 90, 182, 10.1016/j.diabres.2010.06.022
Ligueros-Saylan, 2010, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials, Diabetes Obes Metab, 12, 495, 10.1111/j.1463-1326.2010.01214.x
Lukashevich, 2011, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial, Diabetes Obes Metab, 13, 947, 10.1111/j.1463-1326.2011.01467.x
Del Prato, 2011, Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 13, 258, 10.1111/j.1463-1326.2010.01350.x
Bourdel-Marchasson, 2011, Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap), 39, 7
Pratley, 2007, Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy, Diabetes Care, 30, 3017, 10.2337/dc07-1188
Schweizer, 2011, Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population>=75 years: a pooled analysis from a database of clinical trials, Diabetes Obes Metab, 13, 55, 10.1111/j.1463-1326.2010.01325.x
Schwartz, 2010, Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors, Am J Geriatr Pharmacother, 8, 405, 10.1016/j.amjopharm.2010.10.003
Doucet, 2011, Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus, Curr Med Res Opin, 27, 863, 10.1185/03007995.2011.554532
Barzilai, 2011, Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial, Curr Med Res Opin, 27, 1049, 10.1185/03007995.2011.568059
Waugh, 2010, Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation, Health Technol Assess, 14, 1, 10.3310/hta14360
Scheen AJ. DPP-4 inhibitors are favourable to GLP-1 receptor agonists: yes. Eur J Intern Med 2011 (in press).
Sinha, 2010, Costs and consequences associated with newer medications for glycemic control in type 2 diabetes, Diabetes Care, 33, 695, 10.2337/dc09-1488